Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Friday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms have also commented on VNDA. HC Wainwright assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday. They issued a “buy” rating and a $18.00 price target for the company. Cantor Fitzgerald upped their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

Vanda Pharmaceuticals stock traded up $0.01 during trading hours on Friday, hitting $4.66. The company had a trading volume of 397,341 shares, compared to its average volume of 651,993. The company has a 50-day moving average price of $4.83 and a two-hundred day moving average price of $5.23. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. On average, research analysts forecast that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

Institutional investors have recently modified their holdings of the company. SageView Advisory Group LLC bought a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth approximately $34,000. Meeder Asset Management Inc. purchased a new position in Vanda Pharmaceuticals in the second quarter worth $39,000. ORG Wealth Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the third quarter worth $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,374 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth $61,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.